Skip to main content

Advertisement

Table 1 Patient demographics and disease characteristics

From: Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study

 n = 337, median [IQR] (range) or n (%)
Demographics
 Age at enrolment (years)37 [28, 48] (18, 74)
 Age at diagnosis (years)26 [19, 38] (1, 69)
 Disease duration (years)7 [3, 13] (0, 36)
 Study duration (years)3.2 [1.6, 3.4] (0, 4.3)
 Female325 (96.4%)
 Current smoker at enrolment3 (0.9%)
 Family history of SLE25 (7.4%)
 Education level
  Primary83 (24.8%)
  Secondary96 (28.7%)
  Tertiary156 (46.6%)
Medications use
 Prednisolone ever319 (94.7%)
  TAM Prednisolone dose5.8 [3.7, 9.3] (0, 61)
 Anti-malarials ever129 (38.3%)
 Immunosuppressants ever284 (84.3%)
Clinical indicators
 TAM PGA0.4 [0.3, 0.7] (0.2, 1.9)
 TAM SLEDAI-2K3.5 [2.0, 5.6] (0, 20)
 Organ damage score1 [0, 1] (0, 6)
 Flare (mild/moderate/severe) ever189 (56.1%)
 Organ damage present176 (52.2%)
 Achieved LLDAS ever272 (80.7%)